Efficacy, Tolerability and Acceptability of Biktarvy by TPLWH

NCT04944654 · clinicaltrials.gov ↗

PHASE4

Phase

TERMINATED

Status

1

Enrollment

OTHER

Sponsor class

Stopped Trial set up was delayed, funding support no longer available

Conditions

Human Immunodeficiency Virus

Interventions

DRUG: BIKTARVY 50Mg-200Mg-25Mg Tablet

Sponsor

Chelsea and Westminster NHS Foundation Trust

Collaborators

[object Object]
[object Object]